From Native Lymphocytes to CAR-T Therapy
A brief introduction to key concepts in Chimeric antigen receptor T cell therapy, from the role of T cells in the immune system and the mechanisms by which they exert their function, through the characteristics of T cell receptors, to the basics of CAR-T technology, its application and its current challenges.
Table of Contents
- An introduction to lymphocytes
- Antigen recognition by T-cell receptors
- An introduction to immunoreceptors
- T-cell receptors (TCRs)
- CAR-T for cancer treatment
- CAR vs TCR
- CAR-T for relapse refractory multiple myeloma
- Some issues associated with CAR-T cell therapies
- Limitations of CAR-T therapies and potential solutions
- More on the challenge of recruiting CAR-T cells to solid tumours
- The potential of CAR-T therapy for autoimmune diseases
- CAR-macrophage therapy: a newer cousin to CAR-T therapy
- In vivo CAR therapy
- CAR T cell manufacturing process
1. An introduction to lymphocytes
By Prof. Herman Waldmann – University of Oxford, UK
An excerpt from Introduction to the immune system
2. Antigen recognition by T-cell receptors
By Prof. Herman Waldmann – University of Oxford, UK
An excerpt from Antigen recognition in the immune system
3. An introduction to immunoreceptors
By Prof. Anton van der Merwe – University of Oxford, UK
An excerpt from Immunoreceptors
4. T-cell receptors (TCRs)
By Prof. Anton van der Merwe – University of Oxford, UK
An excerpt from Immunoreceptors
5. CAR-T for cancer treatment
By Prof. Sebastian Kobold – Ludwig-Maximilians-Universität München, Germany
An excerpt from Mode of action of T cells engineered with CAR or TCR for cancer treatment
6. CAR vs TCR
By Dr. Else Marit Inderberg – The Norwegian Radium Hospital, Norway
An excerpt from Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
7. CAR-T for relapse refractory multiple myeloma
By Prof. Paul G. Richardson – Harvard Medical School, USA
An excerpt from The evolving role of novel and next generation therapies in the management of multiple myeloma: relapse refractory multiple myeloma 2
8. Some issues associated with CAR-T cell therapies
By Prof. Sebastian Kobold – Ludwig-Maximilians-Universität München, Germany
An excerpt from Mode of action of T cells engineered with CAR or TCR for cancer treatment
9. Limitations of CAR-T therapies and potential solutions
By Prof. Sebastian Kobold – Ludwig-Maximilians-Universität München, Germany
An excerpt from Mode of action of T cells engineered with CAR or TCR for cancer treatment
10. More on the challenge of recruiting CAR-T cells to solid tumours
By Prof. Ann Ager – Cardiff University, UK
An excerpt from Lymphocyte homing: getting lymphocytes to the right place at the right time
11. The potential of CAR-T therapy for autoimmune diseases
By Dr. Marko Radic – University of Tennessee, USA
An excerpt from The potential of CAR T cells for the treatment of autoimmune diseases
12. CAR-macrophage therapy: a newer cousin to CAR-T therapy
By Prof. Denise Montell – University of California, Santa Barbara, USA
An excerpt from Rac-enhanced CAR immunotherapy: RaceCAR
13. In vivo CAR therapy
By Prof. Dr. Christian Buchholz – Paul-Ehrlich-Institut, Germany
An excerpt from Gene delivery to therapy-relevant cells enables in vivo CAR T cell generation
14. CAR T cell manufacturing process
By Dr. Joseph A. Fraietta – University of Pennsylvania, USA
An excerpt from Immunotherapy: CARs on the fast-track to treat cancer